Nicotinamide mononucleotide adenylyltransferase2 overexpression enhances colorectal cancer cell-kill by Tiazofurin

P. Kusumanchi, Y. Zhang, M. B. Jani, N. H. Jayaram, R. A. Khan, Y. Tang, Asok Antony, H. N. Jayaram

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Colorectal cancer cells exhibit limited cytotoxicity towards Tiazofurin, a pro-drug metabolized by cytosolic nicotinamide mononucleotide adenylyltransferase2 (NMNAT2) to thiazole-4-carboxamide adenine dinucleotide, a potent inhibitor of inosine 5'-monophosphate dehydrogenase required for cellular guanylate synthesis. We tested the hypothesis that colorectal cancer cells that exhibit low levels of NMNAT2 and are refractory to Tiazofurin can be rendered sensitive to Tiazofurin by overexpressing NMNAT2. Transfection of hNMNAT2 resulted in a six- and threefold cytoplasmic overexpression in Caco2 and HT29 cell lines correlating with Tiazofurin-induced enhanced cell-kill. Folate receptors expressed on the cell surface of 30-50% colorectal carcinomas were exploited for cellular targeting with Tiazofurin encapsulated in folate-tethered nanoparticles. Our results indicated that in wild-type colorectal cancer cells, free Tiazofurin-induced EC50 cell-kill was 1500-2000 μM, which was reduced to 66-156 μM in hNMNAT2-overexpressed cells treated with Tiazofurin encapsulated in non-targeted nanoparticles. This efficacy was improved threefold by encapsulating Tiazofurin in folate-tethered nanoparticles to obtain an EC50 cell-kill of 22-59 μM, an equivalent of 100-300 mg m -2 (one-tenth of the approved dose of Tiazofurin in humans), which will result in minimal toxicity leading to cancer cell-kill. This proof-of-principle study suggests that resistance of colorectal cancer cell-kill to Tiazofurin can be overcome by sequentially overexpressing hNMNAT2 and then facilitating the uptake of Tiazofurin by folate-tethered nanoparticles, which enter cells via folate receptors.

Original languageEnglish
Pages (from-to)403-412
Number of pages10
JournalCancer Gene Therapy
Volume20
Issue number7
DOIs
StatePublished - Jul 2013

Fingerprint

tiazofurin
Nicotinamide Mononucleotide
Colorectal Neoplasms
Folic Acid
Nanoparticles
IMP Dehydrogenase
HT29 Cells
Prodrugs

Keywords

  • Folate receptors
  • IMP dehydrogenase inhibitor
  • Nanoparticles
  • Silencing human nicotinamide 5'-mononucleotide adenylyltransferase
  • Targeted therapy
  • Tiazofurin

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Molecular Biology

Cite this

Kusumanchi, P., Zhang, Y., Jani, M. B., Jayaram, N. H., Khan, R. A., Tang, Y., ... Jayaram, H. N. (2013). Nicotinamide mononucleotide adenylyltransferase2 overexpression enhances colorectal cancer cell-kill by Tiazofurin. Cancer Gene Therapy, 20(7), 403-412. https://doi.org/10.1038/cgt.2013.33

Nicotinamide mononucleotide adenylyltransferase2 overexpression enhances colorectal cancer cell-kill by Tiazofurin. / Kusumanchi, P.; Zhang, Y.; Jani, M. B.; Jayaram, N. H.; Khan, R. A.; Tang, Y.; Antony, Asok; Jayaram, H. N.

In: Cancer Gene Therapy, Vol. 20, No. 7, 07.2013, p. 403-412.

Research output: Contribution to journalArticle

Kusumanchi, P, Zhang, Y, Jani, MB, Jayaram, NH, Khan, RA, Tang, Y, Antony, A & Jayaram, HN 2013, 'Nicotinamide mononucleotide adenylyltransferase2 overexpression enhances colorectal cancer cell-kill by Tiazofurin', Cancer Gene Therapy, vol. 20, no. 7, pp. 403-412. https://doi.org/10.1038/cgt.2013.33
Kusumanchi, P. ; Zhang, Y. ; Jani, M. B. ; Jayaram, N. H. ; Khan, R. A. ; Tang, Y. ; Antony, Asok ; Jayaram, H. N. / Nicotinamide mononucleotide adenylyltransferase2 overexpression enhances colorectal cancer cell-kill by Tiazofurin. In: Cancer Gene Therapy. 2013 ; Vol. 20, No. 7. pp. 403-412.
@article{47d198b923234eb0b85bc08905829441,
title = "Nicotinamide mononucleotide adenylyltransferase2 overexpression enhances colorectal cancer cell-kill by Tiazofurin",
abstract = "Colorectal cancer cells exhibit limited cytotoxicity towards Tiazofurin, a pro-drug metabolized by cytosolic nicotinamide mononucleotide adenylyltransferase2 (NMNAT2) to thiazole-4-carboxamide adenine dinucleotide, a potent inhibitor of inosine 5'-monophosphate dehydrogenase required for cellular guanylate synthesis. We tested the hypothesis that colorectal cancer cells that exhibit low levels of NMNAT2 and are refractory to Tiazofurin can be rendered sensitive to Tiazofurin by overexpressing NMNAT2. Transfection of hNMNAT2 resulted in a six- and threefold cytoplasmic overexpression in Caco2 and HT29 cell lines correlating with Tiazofurin-induced enhanced cell-kill. Folate receptors expressed on the cell surface of 30-50{\%} colorectal carcinomas were exploited for cellular targeting with Tiazofurin encapsulated in folate-tethered nanoparticles. Our results indicated that in wild-type colorectal cancer cells, free Tiazofurin-induced EC50 cell-kill was 1500-2000 μM, which was reduced to 66-156 μM in hNMNAT2-overexpressed cells treated with Tiazofurin encapsulated in non-targeted nanoparticles. This efficacy was improved threefold by encapsulating Tiazofurin in folate-tethered nanoparticles to obtain an EC50 cell-kill of 22-59 μM, an equivalent of 100-300 mg m -2 (one-tenth of the approved dose of Tiazofurin in humans), which will result in minimal toxicity leading to cancer cell-kill. This proof-of-principle study suggests that resistance of colorectal cancer cell-kill to Tiazofurin can be overcome by sequentially overexpressing hNMNAT2 and then facilitating the uptake of Tiazofurin by folate-tethered nanoparticles, which enter cells via folate receptors.",
keywords = "Folate receptors, IMP dehydrogenase inhibitor, Nanoparticles, Silencing human nicotinamide 5'-mononucleotide adenylyltransferase, Targeted therapy, Tiazofurin",
author = "P. Kusumanchi and Y. Zhang and Jani, {M. B.} and Jayaram, {N. H.} and Khan, {R. A.} and Y. Tang and Asok Antony and Jayaram, {H. N.}",
year = "2013",
month = "7",
doi = "10.1038/cgt.2013.33",
language = "English",
volume = "20",
pages = "403--412",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Nicotinamide mononucleotide adenylyltransferase2 overexpression enhances colorectal cancer cell-kill by Tiazofurin

AU - Kusumanchi, P.

AU - Zhang, Y.

AU - Jani, M. B.

AU - Jayaram, N. H.

AU - Khan, R. A.

AU - Tang, Y.

AU - Antony, Asok

AU - Jayaram, H. N.

PY - 2013/7

Y1 - 2013/7

N2 - Colorectal cancer cells exhibit limited cytotoxicity towards Tiazofurin, a pro-drug metabolized by cytosolic nicotinamide mononucleotide adenylyltransferase2 (NMNAT2) to thiazole-4-carboxamide adenine dinucleotide, a potent inhibitor of inosine 5'-monophosphate dehydrogenase required for cellular guanylate synthesis. We tested the hypothesis that colorectal cancer cells that exhibit low levels of NMNAT2 and are refractory to Tiazofurin can be rendered sensitive to Tiazofurin by overexpressing NMNAT2. Transfection of hNMNAT2 resulted in a six- and threefold cytoplasmic overexpression in Caco2 and HT29 cell lines correlating with Tiazofurin-induced enhanced cell-kill. Folate receptors expressed on the cell surface of 30-50% colorectal carcinomas were exploited for cellular targeting with Tiazofurin encapsulated in folate-tethered nanoparticles. Our results indicated that in wild-type colorectal cancer cells, free Tiazofurin-induced EC50 cell-kill was 1500-2000 μM, which was reduced to 66-156 μM in hNMNAT2-overexpressed cells treated with Tiazofurin encapsulated in non-targeted nanoparticles. This efficacy was improved threefold by encapsulating Tiazofurin in folate-tethered nanoparticles to obtain an EC50 cell-kill of 22-59 μM, an equivalent of 100-300 mg m -2 (one-tenth of the approved dose of Tiazofurin in humans), which will result in minimal toxicity leading to cancer cell-kill. This proof-of-principle study suggests that resistance of colorectal cancer cell-kill to Tiazofurin can be overcome by sequentially overexpressing hNMNAT2 and then facilitating the uptake of Tiazofurin by folate-tethered nanoparticles, which enter cells via folate receptors.

AB - Colorectal cancer cells exhibit limited cytotoxicity towards Tiazofurin, a pro-drug metabolized by cytosolic nicotinamide mononucleotide adenylyltransferase2 (NMNAT2) to thiazole-4-carboxamide adenine dinucleotide, a potent inhibitor of inosine 5'-monophosphate dehydrogenase required for cellular guanylate synthesis. We tested the hypothesis that colorectal cancer cells that exhibit low levels of NMNAT2 and are refractory to Tiazofurin can be rendered sensitive to Tiazofurin by overexpressing NMNAT2. Transfection of hNMNAT2 resulted in a six- and threefold cytoplasmic overexpression in Caco2 and HT29 cell lines correlating with Tiazofurin-induced enhanced cell-kill. Folate receptors expressed on the cell surface of 30-50% colorectal carcinomas were exploited for cellular targeting with Tiazofurin encapsulated in folate-tethered nanoparticles. Our results indicated that in wild-type colorectal cancer cells, free Tiazofurin-induced EC50 cell-kill was 1500-2000 μM, which was reduced to 66-156 μM in hNMNAT2-overexpressed cells treated with Tiazofurin encapsulated in non-targeted nanoparticles. This efficacy was improved threefold by encapsulating Tiazofurin in folate-tethered nanoparticles to obtain an EC50 cell-kill of 22-59 μM, an equivalent of 100-300 mg m -2 (one-tenth of the approved dose of Tiazofurin in humans), which will result in minimal toxicity leading to cancer cell-kill. This proof-of-principle study suggests that resistance of colorectal cancer cell-kill to Tiazofurin can be overcome by sequentially overexpressing hNMNAT2 and then facilitating the uptake of Tiazofurin by folate-tethered nanoparticles, which enter cells via folate receptors.

KW - Folate receptors

KW - IMP dehydrogenase inhibitor

KW - Nanoparticles

KW - Silencing human nicotinamide 5'-mononucleotide adenylyltransferase

KW - Targeted therapy

KW - Tiazofurin

UR - http://www.scopus.com/inward/record.url?scp=84880918449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880918449&partnerID=8YFLogxK

U2 - 10.1038/cgt.2013.33

DO - 10.1038/cgt.2013.33

M3 - Article

C2 - 23764899

AN - SCOPUS:84880918449

VL - 20

SP - 403

EP - 412

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 7

ER -